From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Synonyms N-n-Butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide
CAS Number
PubChem CID
Chemical and physical data
Formula C34H55NO3
Molar mass 525.818 g/mol
3D model (JSmol)

ICI-164384, also known as N-n-butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide, is a steroidal antiestrogen and a synthetic derivative of estradiol which is closely related to fulvestrant and was never marketed.[1][2] It is a silent antagonist of the estrogen receptor (ER) with no intrinsic estrogenic activity and hence is a pure antiestrogen, unlike selective estrogen receptor modulators (SERMs) like tamoxifen.[1][2] The drug was under development by AstraZeneca for the treatment of breast cancer but was discontinued in favor of fulvestrant,[3] which is very similar to ICI-164384 but is more potent in comparison.[4]

See also[edit]


  1. ^ a b Edward J. Pavlik (6 December 2012). Estrogens, Progestins, and Their Antagonists: Health Issues. Springer Science & Business Media. pp. 133–. ISBN 978-1-4612-4096-9. 
  2. ^ a b A. Howell (15 October 1990). The Role of Antihormones. CRC Press. pp. 119–124. ISBN 978-1-85070-295-5. 
  3. ^ https://adisinsight.springer.com/drugs/800000792[permanent dead link]
  4. ^ William R. Miller; James N. Ingle (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 64–. ISBN 978-0-203-90983-6. 

External links[edit]